An Endogenous Substance with Clonidine-like Properties: Selective Binding to Imidazole Sites in the Ventrolateral Medulla
Authors
Affiliations
We sought to characterize the interactions of an endogenous clonidine-displacing substance (CDS) with the specific receptor sites to which clonidine and its analogs bind: (a) the non-adrenergic imidazole binding site, which is present in the ventrolateral medulla (VLM) but not the frontal cortex, (b) high-affinity and (c) low-affinity states of the alpha 2-adrenergic receptor, and (d) the alpha 1-adrenergic receptor. CDS, like clonidine, potently and completely inhibited specific p-[3H]aminoclonidine binding to membranes from the VLM or from the frontal cortex. Both CDS and clonidine bound with highest affinity to imidazole binding sites in the VLM, both were 3-fold selective for high-affinity over low-affinity alpha 2-adrenergic receptors, and both exhibited lowest affinity for alpha 1-adrenergic receptors. Unlike clonidine, CDS exhibited 30-fold selectivity for imidazole over alpha 2-adrenergic receptors but showed only a weak preference for alpha 2- over alpha 1-adrenergic receptors, indicating that CDS and clonidine are not identical. We conclude that CDS is an endogenous clonidine-like substance which may be the natural ligand for imidazole binding sites in the VLM. The receptor-binding properties of CDS are consistent with the view that it is a unique and as yet unrecognized compound.
Adrenergic nervous system in heart failure: pathophysiology and therapy.
Lymperopoulos A, Rengo G, Koch W Circ Res. 2013; 113(6):739-53.
PMID: 23989716 PMC: 3843360. DOI: 10.1161/CIRCRESAHA.113.300308.
Central mechanisms of abnormal sympathoexcitation in chronic heart failure.
Kishi T, Hirooka Y Cardiol Res Pract. 2012; 2012:847172.
PMID: 22919539 PMC: 3420224. DOI: 10.1155/2012/847172.
Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.
Zhang Y, Kimelberg H Curr Neuropharmacol. 2008; 3(4):317-23.
PMID: 18369397 PMC: 2268994. DOI: 10.2174/157015905774322534.
The control of adrenergic function in heart failure: therapeutic intervention.
Clark A, Cleland J Heart Fail Rev. 2005; 5(1):101-14.
PMID: 16228919 DOI: 10.1023/A:1009854325711.
Raasch W, Schafer U, Qadri F, Dominiak P Br J Pharmacol. 2002; 135(3):663-72.
PMID: 11834614 PMC: 1573177. DOI: 10.1038/sj.bjp.0704513.